Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 8, 2008 - Issue 11
Submit an article Journal homepage
42
Views
3
CrossRef citations to date
0
Altmetric
Review

Determining glioma response to radiation therapy using recombinant peptides

Roberto Diaz Department of Radiation Oncology, Vanderbilt University Medical Center, 1301 Medical Center Drive, B-902 TVC, Nashville, TN, 37232, USA. [email protected]
,
Ralph J Passarella Department of Radiation Oncology, Vanderbilt University Medical Center, 1301 Medical Center Drive, B-902 TVC, Nashville, TN, 37232, USA
&
Dennis E Hallahan Department of Radiation Oncology, Vanderbilt University Medical Center, 1301 Medical Center Drive, B-902 TVC, Nashville, TN, 37232, USA
Pages 1787-1796 | Published online: 10 Jan 2014

References

  • Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
  • Carpentier AF. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol.4(1), 4–5 (2005).
  • Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J. Neurosurg.88(1), 1–10 (1998).
  • Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin. Oncol.31(5), 635–644 (2004).
  • Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
  • Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat. Rev. Drug Discov.7(7), 591–607 (2008).
  • Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J. Nucl. Med.49(Suppl. 2), 5S–23S (2008).
  • Mankoff DA. A definition of molecular imaging. J. Nucl. Med.48(6), 18N–21N (2007).
  • Dinca EB, Sarkaria JN, Schroeder MA et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J. Neurosurg.107(3), 610–616 (2007).
  • Lamfers ML, Fulci G, Gianni D et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther.14(6), 779–788 (2006).
  • Montet X, Ntziachristos V, Grimm J, Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res.65(14), 6330–6336 (2005).
  • Hsu AR, Cai W, Veeravagu A et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J. Nucl. Med.48(3), 445–454 (2007).
  • Rehemtulla A, Hall DE, Stegman LD et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging1(1), 43–55 (2002).
  • Chenevert TL, Stegman LD, Taylor JM et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl Cancer Inst.92(24), 2029–2036 (2000).
  • Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin. Cancer Res.13(6), 1839–1846 (2007).
  • Moffat BA, Chenevert TL, Meyer CR et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia8(4), 259–267 (2006).
  • Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging10(3), 223–232 (1999).
  • Yankeelov TE, DeBusk LM, Billheimer DD et al. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J. Magn. Reson. Imaging24(5), 1140–1147 (2006).
  • Yankeelov TE, Luci JJ, Lepage M et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn. Reson. Imaging23(4), 519–529 (2005).
  • Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol.21(21), 3955–3964 (2003).
  • Mardor Y, Pfeffer R, Spiegelmann R et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high β-value diffusion-weighted magnetic resonance imaging. J. Clin. Oncol.21(6), 1094–1100 (2003).
  • Mardor Y, Roth Y, Ochershvilli A et al. Pretreatment prediction of brain tumors’ response to radiation therapy using high β-value diffusion-weighted MRI. Neoplasia6(2), 136–142 (2004).
  • Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
  • Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using ‘one-bead one-compound’ combinatorial libraries. Mol. Cancer Ther.4(5), 806–813 (2005).
  • Krumpe LRH, Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int. J. Peptide Res. Therapeut.12(1), 79–91 (2006).
  • Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA101(51), 17867–17872 (2004).
  • van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry31(1), 1–9 (1998).
  • Kolodgie FD, Petrov A, Virmani R et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation108(25), 3134–3139 (2003).
  • Narula J, Acio ER, Narula N et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med.7(12), 1347–1352 (2001).
  • van de Wiele C, Lahorte C, Vermeersch H et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J. Clin. Oncol.21(18), 3483–3487 (2003).
  • Belhocine T, Steinmetz N, Hustinx R et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res.8(9), 2766–2774 (2002).
  • Lahorte CM, van de Wiele C, Bacher K et al. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans. Nucl. Med. Comm.24(8), 871–880 (2003).
  • Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers66(3), 184–199 (2002).
  • Nilsson F, Tarli L, Viti F, Neri D. The use of phage display for the development of tumour targeting agents. Adv. Drug Deliv. Rev.43(2–3), 165–196 (2000).
  • Ladner RC. Polypeptides from phage display. A superior source of in vivo imaging agents. Q J. Nucl. Med.43(2), 119–124 (1999).
  • Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol.315(5), 1063–1073 (2002).
  • Rusckowski M, Qu T, Pullman J et al. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J. Nucl. Med.41(2), 363–374 (2000).
  • Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med.49(Suppl. 2), 113S–128S (2008).
  • Hallahan DE, Staba-Hogan MJ, Virudachalam S, Kolchinsky A. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res.58(22), 5216–5220 (1998).
  • Hallahan D, Clark ET, Kuchibhotla J, Gewertz BL, Collins T. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochem. Biophys. Res. Commun.217(3), 784–795 (1995).
  • Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res.56(22), 5150–5155 (1996).
  • Hallahan DE, Virudachalam S. Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung. Cancer Res.57(11), 2096–2099 (1997).
  • Hallahan DE, Virudachalam S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc. Natl Acad. Sci. USA94(12), 6432–6437 (1997).
  • Hallahan DE. Radiation-mediated gene expression in the pathogenesis of the clinical radiation response. Semin. Radiat. Oncol.6(4), 250–267 (1996).
  • Hallahan DE. Introduction. Semin. Radiat. Oncol.6(4), 243–244 (1996).
  • Hallahan DE, Virudachalam S. Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat. Res.152(1), 6–13 (1999).
  • Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther.7(1), 13–19 (2000).
  • Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res.62(16), 4671–4677 (2002).
  • Hallahan D, Geng L, Qu S et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell.3(1), 63–74 (2003).
  • Hallahan DE, Geng L, Cmelak AJ et al. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J. Control Release74(1–3), 183–191 (2001).
  • Geng L, Osusky K, Konjeti S, Fu A, Hallahan D. Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J. Control Release99(3), 369–381 (2004).
  • Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res.63(14), 4009–4016 (2003).
  • Lu B, Geng L, Musiek A et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int. J. Radiat. Oncol. Biol. Phys.58(3), 844–850 (2004).
  • Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science279(5349), 377–380 (1998).
  • Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature – a potential therapeutic target. Br. J. Cancer.72(2), 257–267 (1995).
  • Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell79(7), 1157–1164 (1994).
  • Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res.59(12), 2869–2874 (1999).
  • Ellerby HM, Arap W, Ellerby LM et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med.5(9), 1032–1038 (1999).
  • Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest. New Drugs15(1), 15–28 (1997).
  • Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res.14(1), 2–10 (1997).
  • Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem.274(17), 11593–11598 (1999).
  • Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature380(6572), 364–366 (1996).
  • Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev.58(15), 1622–1654 (2006).
  • Han Z, Fu A, Wang H et al. Noninvasive assessment of cancer response to therapy. Nat. Med.14(3), 343–349 (2008).
  • Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell Biochem.90(3), 509–517 (2003).
  • Lee SM, Lee EJ, Hong HY et al. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res.5(1), 11–19 (2007).
  • Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia8(9), 772–780 (2006).
  • Ho IA, Lam PY, Hui KM. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum. Gene Ther.15(8), 719–732 (2004).
  • Spear MA, Breakefield XO, Beltzer J et al. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Ther.8(7), 506–511 (2001).
  • Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett.171(2), 153–164 (2001).
  • Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell. Dev. Biol.12, 697–715 (1996).
  • Smith JW, Cheresh DA. The Arg–Gl–Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61–203 of the β subunit. J. Biol. Chem.263(35), 18726–18731 (1988).
  • Wu Y, Zhang X, Xiong Z et al. microPET imaging of glioma integrin αvβ3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med.46(10), 1707–1718 (2005).
  • Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest.103(9), 1227–1230 (1999).
  • Haubner R. αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging33(Suppl. 1), 54–63 (2006).
  • Horton MA. The αvβ3 integrin ‘vitronectin receptor’. Int. J. Biochem. Cell Biol.29(5), 721–725 (1997).
  • Haubner R, Wester HJ, Reuning U et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med.40(6), 1061–1071 (1999).
  • Haubner R, Wester HJ, Weber WA et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res.61(5), 1781–1785 (2001).
  • Janssen ML, Oyen WJ, Dijkgraaf I et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res.62(21), 6146–6151 (2002).
  • van Hagen PM, Breeman WA, Bernard HF et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer90(4), 186–198 (2000).
  • Beer AJ, Haubner R, Goebel M et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med.46(8), 1333–1341 (2005).
  • Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D, Pierschbacher MD. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin αIIb β3 antagonists. J. Med. Chem.37(1), 1–8 (1994).
  • Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg–Gly–Asp–Xaa on binding specificity in cell adhesion. J. Biol. Chem.262(36), 17294–17298 (1987).
  • Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K, Kikuchi M. Peptide ligands for integrin αvβ3 selected from random phage display libraries. Biochemistry34(12), 3948–3955 (1995).
  • Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the α5 β1 integrin from phage display library. J. Biol. Chem.268(27), 20205–20210 (1993).
  • O’Neil KT, Hoess RH, Jackson SA, Ramachandran NS, Mousa SA, DeGrado WF. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins14(4), 509–515 (1992).
  • Chen X, Hou Y, Tohme M et al. Pegylated Arg–Gly–Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J. Nucl. Med.45(10), 1776–1783 (2004).
  • Chen X, Park R, Hou Y et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging31(8), 1081–1089 (2004).
  • Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol.31(1), 11–19 (2004).
  • Huamani J, Passarella RJ, Onishko HM et al. Rapid assessment of malignant glioma susceptibility to molecular targeted therapy. Int. J. Radiat. Oncol. Biol. Phys.69(3), S149–S149 (2007).
  • Passarella RJ, Diaz R, Hallahan DE. Rapid recognition of glioma response to radiation therapy using recombinant peptides. Presented at: 99th Annual Meeting of the American Association for Cancer Research (AACR). San Diego, CA, USA, 12–16 April 2008 (Abstract 1458).
  • Diaz R, Hariri G, Passarella RJ, Wu H, Fu A, Hallahan DE. Radiation-guided platinum drug delivery using recombinant peptides. Int. J. Radiat. Oncol. Biol. Phys.72(1), S1 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.